Healthcare Equipment and Supplies
Company Overview of Miramar Labs, Inc.
Miramar Labs, Inc. develops medical devices for the treatment of dermatologic medical conditions. It offers miraDry System for the treatment of primary axillary hyperhidrosis and reducing underarm sweat; and miraWave technology, a technology platform that uses microwave energy for treatment in other medical areas, such as oncology, cardiology, and urology, as well as for dermatologic conditions. Miramar Labs, Inc. was formerly known as Foundry Newco X, Inc. The company was founded in 2006 and is based in Santa Clara, California.
2790 Walsh Avenue
Santa Clara, CA 95051
Founded in 2006
Key Executives for Miramar Labs, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chairman of the Board
Chief Financial Officer and Senior Vice President
Vice President of Law and General Counsel
Managing Director for Asia Pacific
Compensation as of Fiscal Year 2015.
Miramar Labs, Inc. Key Developments
Miramar Labs, Inc. Presents at Medical Device Conference 2015, Jun-26-2015 09:30 AM
Jun 22 15
Miramar Labs, Inc. Presents at Medical Device Conference 2015, Jun-26-2015 09:30 AM. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, California, United States. Speakers: Robert Michael Kleine, Chief Executive Officer, President and Director.
Miramar Labs, Inc. Announces Management Changes
Feb 10 14
Miramar Labs, Inc. announced the appointment of R. Michael Kleine as its new president, chief executive officer and a member of its board of directors. Mr. Kleine will succeed Darrell Zoromski, the company's current president and CEO, who had previously announced his intent to step down in order to spend more time with his family. Prior to joining Miramar Labs, Mr. Kleine was most recently the CEO of EndoGastric Solutions (EGS) and will continue to serve as its Chairman of the Board. Mr. Zoromski played an active role in the CEO search and will continue to support the company in the coming months to ensure a smooth leadership transition.
Miramar Labs Announces CE Mark Approval for the miraDry(R) System to Treat Bothersome Underarm Sweat
Jan 6 14
Miramar Labs(R) Inc. announced that the miraDry(R) System received Conformite Europeenne (CE) Mark approval for the treatment of primary axillary hyperhidrosis, commonly known as bothersome underarm sweat. Clearance for miraDry was granted by the U.S. Food and Drug Administration in January 2011 following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics followed for 12 months post-treatment. A follow up study was conducted in Canada that showed patients experienced sustained improvement in sweat reduction and quality of life 24-months post treatment.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|